Tagged with Access,

Tunisia Walid Lakhdar, country business unit head for Tunisia and Libya at Pfizer, stresses the company’s ongoing dedication to patients in Tunisia. This was illustrated by the significant investments Pfizer has made in Tunisia after the revolution and still continues to make. Lakhdar talks about Pfizer’s successful partnerships in the country…

Austria Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations. Furthermore, he points out the factors influencing the influx of innovative drugs into Austria, especially in rare diseases, and highlights…

India Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges of the current pricing climate, and the ultimate goal of providing affordable and accessible medicines to the nation’s roughly 1.3…

Bulgaria Stanimir Hasurdjiev explains the key role of the National Patients’ Organization (NPO) in Bulgaria and discusses the main areas that he is working on to ensure that patients are heard and can benefit from the best treatments and care available at a reasonable price.    You are working in different…

Austria Rudolf Wessely, CEO and founder of Gynial, the Austrian leader in oral contraceptives, elaborates on the company’s incredibly fast market penetration since 2007 and explains his expertise in the contraceptive field. Furthermore, he discusses the importance of open communication with gynaecologists and Gynial’s unique product philosophy as well as the…

ARM Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing in terms of market access and stakeholder education in Europe, as well as some of the key breakthroughs that European…

Canada Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients…

Colombia Guillermo Browne, General Manager at MSD Colombia, reveals the strategic importance of the Colombian affiliate, hosting a global data management centre and regional pharmacovigilance operations, while highlighting the company’s commitment to continue advancing the therapeutic value of care and the clinical research landscape in Colombia. With 70 years of presence…

Colombia Carlos Alberto Florez, newly appointed general manager of Aspen Colombia, already has a very clear view on Aspen’s strategic direction, discussing the expansion of the infant nutrition segment and the recent acquisition of anaesthetics lines. He also underlines his passion for start-up businesses and his eagerness to see Aspen evolve…

Colombia Juan Carlos Mejia Hernandez, General Manager of Altadis Farmaceutica, a fresh entrant into the Colombian market, speaks about his strategies for advancing the educational system within the medical community by developing a platform based on digital channels. Mr. Mejia, Altadis Farmaceutica is a recent entrant to the Colombian market, having…

Canada Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends within the country. Lyndal, you established Ipsen’s Canadian affiliate in 2015. First and foremost, what opportunity did Ipsen globally see…

Colombia Guillermo Gómez, managing director of the Andean region at Siemens Healthineers discusses Colombia’s evolution in terms of access to healthcare and investment in life-saving medical equipment, as well as the role Healthineers can play in reducing healthcare system costs and easing patient access. Those are exiting times for Siemens as…